

Research Article

Investigating the Role of Gut Microbiota Dysbiosis in the Pathogenesis and Advancement of Alzheimer's Disease: A Comprehensive Multi-Omics Approach

Mayasa M. Abdulrahman ^{1,*}, , Shahad ihsan kadhum ², 

¹ Computer Engineering Department, College of Engineering, University of Baghdad, Baghdad, Iraq

² Ministry of Health, Baghdad Health Department, Al-Karkh, Baghdad, Iraq.

ARTICLE INFO

Article History

Received 20 Feb 2023

Revised: 18 Apr 2023

Accepted 18 May 2023

Published 15 Jun 2023

Keywords

Gut Microbiota Dysbiosis

Alzheimer's Disease

Pathogenesis

Multi-Omics Approach

Neuroinflammation

Microbiota-Based

Therapy



ABSTRACT

Alzheimer's disease (AD) and other neurodegenerative diseases pose significant global health challenges due to their progressive rate and lack of effective therapies. Recent research suggests an important role for gut bacteria in the incidence and progression of these diseases, but the mechanisms remain elusive. This study used a comprehensive multi-omics approach. When the method was applied, the study used pathways used microbial screening methods with 16S rRNA sequencing and metagenomics to screen working water samples from AD patients and healthy controls to identify specific microbial changes and their relationships between them and disease severity. There was a decrease in beneficial bacteria and an increase in harmful, inflammatory bacteria such as *Escherichia/Shigella*. These microbial changes were associated with moderate cognitive impairment, as measured by Mini Mental Status Examination (MMSE) scores. Analysis of the metabolites indicated that these microbial alterations could affect important pathways, including the production of short-chain fatty acids (SCFAs) and immune modulation, which may increase neurodegeneration and neurodegeneration. Our contributions include identification of species and metabolites, and exploration of potential therapeutic targets. Dysbiotic microbial signatures identified in AD patients and microbial-based interventions, such as probiotics, dietary modifications, and fecal microbial transplantation, have been administered to restore a healthy gut microbiota and reduce some of the symptoms of disease.

1. INTRODUCTION

Neurological diseases such as Alzheimer's and Parkinson's disease are major health challenges worldwide, affecting millions of individuals and placing a heavy burden on the healthcare system. Alzheimer's disease is characterized by amyloid beta plaques and tau tangles in the brain. Accumulation of these proteins causes cognitive decline, progressive memory loss, and behavioral changes. Parkinson's disease affects basic motor function, causing tremor, rigidity, and bradykinesia, and loss of dopamine-producing neurons in the substantia nigra. Despite extensive research, the specific causes of these diseases are elusive, and current treatments are largely symptomatic, offering limited effectiveness in halting disease progression. The trillions of cells that inhabit the thick lining of the gastrointestinal tract. The human gut microbiome plays an important role in maintaining overall health. Recent advances in metagenomics and microbiological studies are shedding light on the fundamental effects of the gut microbiota on peripheral organs, including the brain. This intimate connection between the gut and brain, commonly referred to as the gut-brain axis, is mediated by multiple mechanisms, including immune system, endocrine signaling, and neural communication such as the vagus nerve. Emerging evidence highlights the potential role of gut bacteria in neurodegenerative diseases. Studies have shown that changes in the composition of the gut microbiota, known as dysbiosis, can affect neuropathy, neurological disorders and motor function, contributing to the disease-like conditions of Alzheimer's and Parkinson's occur as, specific micro metabolites, such as short-chain fatty acids (SCFAs) cross blood-brain barrier to neuroprotective or neurotoxic effects, dysbiosis is associated with increased intestinal permeability, causing harmful substances enter the bloodstream and trigger systemic inflammation, which can further influence brain health. The gut-brain axis is its implications for neurological underlying diseases and is most important. By elucidating the complex interactions between the gut microbiota and the central nervous system, researchers can identify new therapeutic targets and strategies to reduce disease symptoms and progression. The aim of this review is through a comprehensive microbial description and analysis of the association with disease progression between the gut microbiota and the development of neurological diseases. Through key microbiota changes and potential therapeutic targets upon

*Corresponding author email: m.abdulrahman85@gmail.com

DOI: <https://doi.org/10.70470/SHIFAA/2023/008>

discovery, this study seeks to pave the way for new microbial-based interventions to potentially improve the quality of life of individuals affected by cation conditions[5].

Fig 1 illustrates the multifaceted mechanisms by which the gut microbiome may affect neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and so on development and progression of these pathways. These pathways are divided into three major mechanisms, each of which contributes to neurodegeneration through specific mechanisms. First, an effect on the immune system has been demonstrated. Gut bacteria produce microbial-associated molecular systems (MAMPs) that stimulate immune cells such as macrophages and T cells. This stimulation leads to cytokine overproduction, resulting in chronic inflammation[6]. Chronic inflammation is detrimental to brain health, as it can disrupt normal nerve function and contribute to the progression of neurodegenerative diseases. Thus, the persistent inflammatory environment induced by intestinal bacteria may be an important factor in the development of these conditions. Second, the figure shows how gut bacteria produce metabolic and neurotransmitters. These bacteria produce a variety of important chemicals such as serotonin (5HT), gamma-aminobutyric acid (GABA), and dopamine, among other neurotransmitters. Once synthesized, these chemicals enter the bloodstream and enter the brain, altering nerve activity and brain function. Imbalances or dysregulation of these hormones can directly affect vascular health and are associated with the progression of periodontal diseases Gut microbes play an important role in creating protection against rheumatoid arthritis conditions about or enhance it by influencing the chemical environment of the brain Finally, matrix the enteric nervous system investigates the stimulation [7] The interaction between intestinal bacteria and the intestinal nervous system releases chemicals such as dopamine, which can activate or inhibit intestinal nerves These nerves communicate directly with, and through, the central nervous system affects brain function. Through this neuronal interaction, gut microbiota can exert a significant influence on the central nervous system and contribute to the progression of arthritis[8].




Fig. 1. Mechanisms linking gut bacteria to neurodegenerative diseases

The primary aim of this review is to investigate the relationship between the gut microbiota and the development and progression of neurodegenerative disease, especially in patients with Alzheimer's disease and Parkinson's disease -Our understanding of brain of the no axis and we seek to enhance its role in rheumatoid arthritis, thus paving the way for the development of new microbial-based agents that can improve symptoms and prevent diseases this weakness has been slow. The research focuses on two major neurodegenerative diseases: Alzheimer's disease and Parkinson's disease. Alzheimer's disease is characterized by cognitive decline, memory loss, and behavioral changes, primarily due to the accumulation of amyloid-beta plaques and tau tangles in the brain, while Parkinson's disease primarily affects motor function, causing tremors, rigidity and bradykinesia, and supplying dopamine to the substantia nigra[9]. loss of productive tissuesBy examining these two distinct but interrelated conditions, the study aims to identify which microorganisms are commonly implicated in a particular disease which may provide insight into their pathogenesis and mechanisms potentially therapeutic Metagenomics

etc. using advanced techniques. Data analysis will include bioinformatics tools and statistical methods to link microbiological data with clinical measures of disease severity and progression. However, the study has several limitations. These include changes in the gut microbiota due to factors such as diet, medication and lifestyle, which can confound results. Furthermore, although correlations can be identified, experimental testing will be required. Another validation to establish a causal relationship between gut bacteria and neurological diseases and treatment strategies can be suggested [10].

2. LITERATURE REVIEW

2.1 Gut Microbiota: Composition and Functions

The human gut microbiome is an incredibly diverse and dynamic group of microorganisms, including bacteria, archaea, bacteria, and fungi, that primarily inhabit the gastrointestinal tract. This complex ecosystem contains microorganisms billions, constituting the most studied species. Gut microbiota exhibit considerable variation over time between individuals as well as within individuals. The main gut bacteria are Bacteroidetes, Firmicutes, Actinobacteria and Proteobacteria. A variety of factors including genetics, diet, age, health status, and environmental factors influence each person's gut microbiome [11]. The diversity and balance of this microbiota is critical to maintaining health, and its disruption can lead to a variety of diseases, including metabolic, inflammatory conditions, and psychological even health issues [12]. The functions of the gut bacteria are multidimensional and crucial to human health. One of the main functions of gut bacteria is digestion and nutrient absorption. These microorganisms help break down carbohydrates, proteins and complex fats that are otherwise inaccessible to human enzymes. For example, some gut bacteria synthesize short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate through digestive fiber oxidation. SCFAs are an energy source for colonocytes, regulate glucose and lipid metabolism, and have effect anti-bacterial. Additionally, the gut microbiota contribute to the synthesis of essential vitamins such as vitamin K and a few B vitamins, which are essential for physiological functions [13]. In addition to digestion, gut bacteria play an important role in the immune system. It supports the development and maturation of the immune system, balancing pro-inflammatory and anti-inflammatory responses. Gut bacteria provide a barrier against pathogens by competing for nutrients and space, producing antimicrobial substances, and stimulating the production of complex fluids and proteins that form the gut epithelial barrier. The interaction between the gut bacteria and the immune system is mediated by bacteria-associated molecular systems (MAMPs). is recognized by pattern recognition receptors (PRRs) on immune cells, resulting in an appropriate immune response and Dysregulation of this delicate balance can cause in chronic inflammation and have been implicated in autoimmune and inflammatory diseases. Gut microbiota is an important component of host metabolism. It affects the metabolism of bile acids, fats, and amino acids, and plays a role in gathering energy from food [14]. Gut-derived metabolites, such as SCFAs and bile acids, act as signaling molecules that affect host metabolic pathways and energy homeostasis. The effects of these metabolites are receptors on host cells so interact, modulating such processes as insulin resistance, fat storage, and appetite regulation. Consequently, changes in gut microbiota composition and function are associated with metabolic syndromes such as obesity, type 2 diabetes mellitus, and nonalcoholic fatty liver disease [15].

2.2 Neurodegenerative Diseases: Pathophysiology and Current Treatments

Alzheimer's disease (AD) is the most common form of dementia, characterized by a progressive decline in cognitive function and memory. AD pathology is characterized by the accumulation of amyloid-beta ($A\beta$) plaques and neurofibrillar tangles of hyperphosphorylated tau protein in the brain. These abnormal protein aggregates interfere with neuronal communication and lead to cell death [16]. The formation of amyloid plaques is initiated by improper cleavage of amyloid precursor protein (APP) by beta-secretase and gamma-secretase, yielding insoluble $A\beta$ peptides. These peptides assemble into oligomers and fibrils, which form poisonous to the nerves. Neurofibrillar tangles, on the other hand, result from abnormal phosphorylation of tau, a protein that stabilizes microtubules. Overphosphorylated tau dissociates from microtubules, leading to their degradation and subsequent neurodegeneration [17]. Inflammation and oxidative stress further exacerbate neuronal injury, contributing to the progression of AD. Genetic factors such as mutations in the APP, PSEN1, and PSEN2 genes, and the presence of the APOE $\epsilon 4$ allele confer the risk of AD. Parkinson's disease (PD) is a neurodegenerative disorder of the main function is great. Notably, there is a loss of dopamine-producing neurons in the substantia nigra pars compacta of the brainstem [18]. Dopamine is an important neurotransmitter that regulates movement, and its deficiency causes the hallmark symptoms of PD, including tremor, rigidity, bradykinesia, and postural instability. The pathology of PD occupies the alpha phase. On the accumulation of α -synuclein protein in Lewy bodies in neurons [19]. These aggregates disrupt cellular homeostasis and lead to neuronal death. Mitochondrial dysfunction and oxidative stress contribute significantly to neuronal loss in PD. Environmental factors such as exposure to pesticides and heavy metals, as well as genetic mutations in genes such as SNCA, LRRK2 and PARK2, have been associated with the onset and progression of the disease. Neuroinflammation also plays an important role in PD, as activated microglia release pro-inflammatory cytokines that further damage dopaminergic neurons. Current therapies for neurodegenerative diseases such as AD and PD are mainly symptomatic and do not stop disease progression. Cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) and NMDA receptor antagonists (memantine) are commonly prescribed to manage cognitive symptoms in AD. These drugs increase neuronal activity but are not pathological the underlying solution. Recently, monoclonal antibodies targeting $A\beta$ plaques, such as aducanumab, have been approved, but their clinical utility is still under review and carries high risks and costs. However, long-term use of levodopa can cause neurological complications such as dyskinesia and physiological changes.

Dopamine agonists (pramipexole, ropinirole) and MAO-B inhibitors (selegiline, rasagiline) are also used to manage [20]. Deep brain stimulation (DBS) is an advanced surgical treatment for PD, providing significant relief for physiological symptoms, but it is invasive and inappropriate for all patients. AD and PD treatment faces the limitation of that the course of the disease cannot be changed. The habitual nature of these treatments highlights the need for novel strategies targeting pathways in pathology [21]. Ongoing research on disease-modifying therapies targeting protein aggregation, neurodegeneration, and mitochondrial dysfunction. Advances in embryonic and cerebral cortex and their effects on neurology diseases logically holds promise for the development of novel therapies that can alter disease progression and also improve patient outcomes.

2.3 The Gut-Brain Axis: Mechanisms of Interaction

The enteric nervous system is the communication system of the central nervous system (CNS) of this complex system, the enteric nervous system of the gut and the brain. It plays an important role in regulating and influencing cognitive and psychological functions. The ENS, commonly called the “second brain,” contains about 100 million neurons embedded in the walls of the gastrointestinal system. It acts independently but also communicates via the autonomic nervous system with the CNS, specifically the vagus nerve, which is an important component of the gut-brain axis. This bidirectional communication means that the brain is unlikely to have access to the gut's functional effects, such as motility and secretion alone, including cognition and behavior. Trillions of microbes living in the gut play an important role in the gut and brain. These microbes influence the brain through many different mechanisms:

1. **Vagus Nerve** : The vagus nerve is the main nerve pathway connecting the gut to the brain. It transmits signals from the gut to the brain, thereby influencing brain function. Fetal bacteria can affect the function of the vagus nerve by producing metabolites such as neurotransmitters. For example, some strains of bacteria can synthesize gamma aminobutyric acid (GABA), a neurotransmitter that modulates neuromuscular excitement and is associated with reduced anxiety and stress. Furthermore, microbial digestive fibers produce butyrate and other short-chain fatty acids (SCFAs), which stimulate afferent neurons and alter brain activity.
2. **Immune System** : Gut-associated lymphoid tissue (GALT) is an important component of the gastrointestinal immune system. Gut bacteria interact with GALT, affecting the immune system that can affect the brain. Dysbiosis, or an imbalance of the gut microbiota, can lead to increased intestinal permeability, commonly referred to as “leaky gut.” This condition allows bacterial toxins and other pro-inflammatory substances to enter the bloodstream and enter the brain, causing neuropathy. Chronic neuropathy is a hallmark of many neurological disorders, including Alzheimer's disease and Parkinson's disease. Gut bacteria also produce microbe-associated molecular patterns (MAMPs) that can activate immune cells, leading to the release of cytokines and other inflammatory mediators that can affect brain function.
3. **Metabolic Pathways** : Gut cells are involved in a variety of metabolic processes that affect brain health. For example, SCFAs such as acetate, propionate, and butyrate are produced from the fermentation of digestive fibers by gut bacteria. These SCFAs are able to cross the blood-brain barrier and influence neurotransmission and behavior. Butyrate in particular has anti-inflammatory and tissue-protective properties. In addition, gut bacteria produce vitamins such as B12 and K, which are essential for nerve function and mental health. Disruption of these metabolites due to dysbiosis can lead to deficiencies or imbalances in these vital physiological processes, which can affect brain health and contribute to neurodegenerative diseases.

Table I summarizes the main mechanisms of communication along the gut-brain axis, identifying their causes, criteria for measurement, and distinguishing between concrete (pattern observations) and deep information (challenges) between the mechanisms. The mechanisms include the vagus nerve, the immune system, and metabolic pathways. Each mechanism is associated with specific causes, such as neurotransmitter production, dysbiosis, and digestive fiber inflammation. The table lists measurable factors such as neurotransmitter levels, biomarkers of inflammation, and SCFA levels, providing true case examples illustrating these interactions, such as reduced anxiety and increased GABA levels. This comprehensive overview contributes to our understanding of the practical challenges and challenges in studying the spinal cord and brainstem.

TABLE I. TABLE: GUT-BRAIN AXIS MECHANISMS OF INTERACTION, CAUSES, AND MEASUREMENT PARAMETERS

Mechanism of Interaction	Causes/Factors	Parameters of Measures	True Cases (Example Findings)	Hard Cases (Challenges)
Vagus Nerve	Production of neurotransmitters (e.g., GABA)	- Neurotransmitter levels (e.g., GABA, SCFAs)	Elevated GABA levels linked to reduced anxiety	Variability in individual responses
	Production of SCFAs (e.g., butyrate)	- Vagal nerve activity (measured by electrophysiology)	Increased vagal tone associated with improved mood	Difficulty in measuring vagal nerve activity in vivo
		- Heart rate variability (HRV)	Higher HRV linked to better stress resilience	Invasive procedures for direct measurement
Immune System	Dysbiosis leading to increased intestinal permeability	- Biomarkers of inflammation (e.g., cytokines)	Elevated cytokines correlated with neuroinflammation	Identifying specific microbial triggers

	Production of MAMPs	- Intestinal permeability (e.g., zonulin levels)	Higher zonulin levels in patients with neurodegenerative diseases	Controlling for confounding factors like diet
		- Endotoxin levels in blood	Elevated endotoxin levels linked to systemic inflammation	Heterogeneity in immune responses
Metabolic Pathways	Fermentation of dietary fibers	- SCFA concentrations in blood	Increased butyrate levels associated with neuroprotection	Variations in dietary intake and gut microbiota composition
	Vitamin synthesis (e.g., B12, K)	- Vitamin levels in blood	Higher B12 levels linked to cognitive health	Complex interactions affecting vitamin absorption
		- Metabolite profiling (e.g., LC-MS)	Specific metabolites associated with improved brain function	Technical complexity and cost of metabolomic analyses

2.4 Previous Studies on Gut Microbiota and Neurodegeneration

Over the past decade, several studies have examined the relationship between gut bacteria and neurodegenerative diseases, shedding light on how bacterial communities in the gut influence brain health. Seminal research by Cryan and Dinan (2012) provided the first evidence of a gut-brain axis. This pioneering work laid the foundation for subsequent research into the role of microorganisms in neurological disease. A landmark study in 2016 by Sampson et al. investigated the role of gut bacteria in Parkinson's disease (PD) using a mouse model. The researchers found that germ-free mice lacking the gut virus had poorer function and accumulation of alpha-synuclein in the brain compared to conventionally raised mice, a hallmark of PD. Synuclein pathology increased, revealing a direct effect of gut microbes on neurodegeneration. In 2019, Vogt et al. focused on Alzheimer's disease (AD), examined the gut microbiota status of AD patients compared with healthy controls. The researchers found significant differences in the abundance of specific microorganisms, including decreases in inflammatory bacteria such as Eubacterium and increases in inflammatory pathogens such as Escherichia/Shigella. These findings suggest that embryonic changes may have contributed to the pathogenesis of neurodegeneration and AD. Further supporting these findings, a meta-analysis by Xu and Wang (2020) reviewed more than 20 studies on gut microbiota and neurodegenerative diseases, concluding that panic disorder is consistently associated with PD and AD [21]. Meta-analysis revealed common microbial changes, such as increased numbers of pathogenically supportive proteobacteria and decreased numbers of beneficial firmicutes, across studies, underlining the potential role of gut microbiota. It has been shown to exacerbate the progression of neurodegenerative disease. Support for the correlation between gut microbes and neurodegenerative diseases of specific changes in microbes associated with the conditions. Have been found, many studies have found that fatty chain bacteria short (SCFA) such as Faecalibacterium and Roseburia are lower in PD and AD patients. SCFAs, especially butyrate, have anti-inflammatory and neuroprotective properties, suggesting that their deficiency may exacerbate neurodegeneration [22]. In addition to the microbial composition, the gut-brain has several potential causal mechanisms by which gut microbes can influence neurodegenerative diseases. One important factor is neurodegeneration. Dysbiosis can increase intestinal permeability, allowing endotoxins such as lipopolysaccharide (LPS) to enter the bloodstream and trigger systemic inflammation. Elevated LPS levels have been observed in patients with PD and AD, respectively is associated with increased incidence and neurological damage [23]. Another key mechanism is the production of microbial metabolites that can cross the blood-brain barrier and affect brain function. For example, some gut microbes produce amyloid-like proteins that can increase neuronal amyloid accumulation, potentially leading to accelerated amyloid plaque formation in AD. Furthermore, gut microbiota acquire neurogenesis such as serotonin, dopamine, and GABA that influence mood, mood, and motor function. Changes in microbial populations that play an important role in control can disrupt these neurotransmitter pathways, contributing to muscle of diseases producing neurological symptoms [24]. The interaction between gut bacteria and the immune system also plays an important role in rheumatoid arthritis. Gut bacteria can modulate the function of microglia, the immune cells of the brain, by producing signaling molecules such as SCFAs and other metabolites. Microglial dysfunction can lead to chronic neurodegeneration results, a common feature in PD and AD [25].

3. METHODOLOGY

3.1 Study Design

The study was well designed to investigate the association between gut microbial composition and the development of neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD). Using an integrated study design, cross-sectional and longitudinal research designs were used to this end.

A cross-sectional design was chosen to provide a snapshot of the gut microbiota composition at a specific time point in AD and PD patients. This approach allowed comparison of microbiota profiles of neurodegenerative disease patients and healthy control subjects. By analyzing these data, researchers aimed to identify significant differences in microbial composition that may be associated with rheumatoid arthritis diseases. The cross-sectional design has advantages for the ability to rapidly gather data and make inferences about changes affected by microorganisms and their possible relationship to the disease.

In contrast, using a longitudinal design to evaluate longitudinal changes in gut microbiota and their association with disease progression, participants were followed for several years, and gut microbial samples were periodically collected and

clinically examined. This design enabled the study to capture complex changes in microbial communities and their potential impact on the course of AD and PD. Longitudinal studies are particularly valuable in understanding causal and temporal relationships, providing insight into how changes in the gut microbiome may precede or accompany disease progression. Specific inclusion and exclusion criteria for patient selection were established to ensure the reliability and validity of the study.

Inclusion Criteria:

1. Diagnosis of neurodegeneration: Participants had to have a clinical diagnosis of Alzheimer's disease or Parkinson's disease, by a neurologist based on established diagnostic criteria so emphasizes
2. Age range: Participants aged 50-85 years were included, as this age group accounted for the majority of AD and PD cases.
3. Consent: All participants or their legal guardians gave informed consent to participate in the study.
4. Ability to provide samples: Participants had to be able to provide urine samples for cervical bacterial analysis and undergo periodic clinical examination.

Exclusion Criteria:

1. Recent use of antibiotics: Participants who used antibiotics in the three months before the study were excluded, as antibiotics can change gut microbiome.
2. Persistent gastrointestinal disorders were excluded: Individuals with severe gastrointestinal disorders such as pancreatitis, celiac disease, or chronic pancreatitis were excluded to avoid confounding effects on fetuses on microorganisms
3. Other neurological diseases: To maintain the focus on AD and PD, patients with other major neurological or psychiatric disorders such as multiple sclerosis or schizophrenia were excluded.
4. Serious comorbid conditions: Serious comorbid conditions, such as advanced cancer or end-stage renal disease, were excluded due to their potential impact on general health and uterus because of microorganisms.

That the combination of cross-sectional longitudinal design and stringent inclusion and exclusion criteria provided a robust framework for examining the association between gut bacteria and neurological diseases A comprehensive approach observed that the findings were reliable and relevant, and paved the way for future research and possible therapeutic interventions targeting the gut-brain axis in neurodegenerative diseases.

3.2 Sample Collection and Microbial Profiling

Accurate collection of gut microbial samples is an important step in studying the role of microbes in neurological diseases. The primary method for collection of gut microorganisms is stool samples. This noninvasive technique is preferred because of its simplicity and comprehensive representation of the gut bacteria. Participants were provided with sterile, sealed containers and detailed instructions for sample collection at home to ensure accuracy and minimal contamination. They advised to avoid antibiotics, probiotics, and other substances that can alter the gut microbiota at least one month before sampling. Once samples are collected, samples are stored in cold chain on to preserve the microorganisms until they can be processed in the laboratory. This process generally requires samples to be stored at -80°C to allow microbial survival and DNA integrity. Once gut microbiome samples are collected, microbial profiling is performed to identify and quantify the diversity of microbial species present. Two major approaches are 16S rRNA sequencing and metagenomics.

1. 16S rRNA sequencing: This method targets the 16S ribosomal RNA gene, a highly conserved region in the bacterial genome that contains hypervariable regions to identify bacterial species. The process begins with DNA extraction of water samples, followed by polymer chain reaction (PCR) amplification of the 16S rRNA gene. The amplified genes are then sequenced using high-end sequencing technologies such as Illumina MiSeq or NextSeq. Bioinformatics tools are used to analyze sequencing data, providing insight into the composition and abundance of bacterial species per sample. 16S rRNA sequencing is highly efficient for bacterial species diversity and community structure detection, making it a widely used method for gut microbiology.
2. Metagenomics : In contrast to 16S rRNA sequencing, metagenomics involves sequencing all the genomic elements of a microbial community in a sample. This provides insight into the microbiome, which includes bacteria, archaea, bacteria and fungi. The process begins with the extraction of microbial DNA from water samples, which are then fractionated and sequenced using high throughput platforms such as Illumina HiSeq or NovaSeq. The resulting data are large and complex, and demanding that advanced bioinformatics pipelines integrate, record and analyze data. Metagenomics not only identifies microbial presence but also provides functional insights through genes involved in metabolic pathways and potential microbial-host interactions. This approach is invaluable in understanding gut microbial function and role in health and disease.

The two approaches, 16S rRNA sequencing and metagenomics, offer distinct advantages and may be complementary. Although 16S rRNA sequencing is cost-effective and suitable for large-scale studies focused on bacterial community structure, metagenomics provides a deeper understanding of microbial diversity and function, albeit at a cost it is more difficult to The work is clear.

Table II shows the important factors used in the analysis of the gut microbiota and its corresponding value measures and its association with rheumatoid arthritis. It consists of two main parts: sample collection and microbial profiling. Basic sample collection parameters include sample type (water), storage temperature (-80°C), and storage duration to ensure microbial sample integrity and function. In Microbial Profiling the section describes 16S rRNA architecture and metagenomics

methods, target genes, sequencing in depth platforms, data output, taxonomic resolution, and functional analysis. After highlighting this aspect; bioinformatics analysis parameters such as DNA extraction efficiency, PCR efficiency, data quality, microbial diversity, and relative abundance are included in the table. These detailed measurements and measurements are necessary to obtain accurate and reliable information. It occurs.

TABLE II. PARAMETERS AND VALUE MEASURES FOR SAMPLE COLLECTION AND MICROBIAL PROFILING

Parameter	Method	Value Measure
Sample Collection		
Sample Type	Stool Sample	Non-invasive collection
Storage Temperature	-80°C	Ensures microbial integrity
Storage Duration	Until processing (typically days to weeks)	Maintains sample viability
Microbial Profiling		
16S rRNA Sequencing		
Target Gene	16S rRNA gene	Conserved bacterial gene
Sequencing Platform	Illumina MiSeq/NextSeq	High-throughput sequencing
Data Output	Reads/Sequences	Number of sequences generated
Taxonomic Resolution	Species/Genus level	Level of bacterial identification
Metagenomics		
Sequencing Coverage	Whole genome	Comprehensive microbial profiling
Sequencing Platform	Illumina HiSeq/NovaSeq	High-throughput sequencing
Data Output	Reads/Sequences	Number of sequences generated
Functional Analysis	Gene annotation	Identification of metabolic pathways
Bioinformatics Analysis		
DNA Extraction Efficiency	DNA yield (ng/μL)	Amount of DNA extracted
PCR Efficiency	Amplification success	Quality of amplified DNA
Data Quality	Quality scores (Q20, Q30)	Sequencing accuracy
Microbial Diversity	Alpha and Beta diversity indices	Diversity within and between samples
Relative Abundance	Percentage (%)	Proportion of microbial taxa

3.3 Data Analysis

Analysis of microbial data from 16S rRNA sequencing and metagenomics involves a variety of sophisticated bioinformatics tools and computational methods for processing, interpreting, and visualizing large amounts of data. This step ensures that only high-quality data are used for subsequent analysis. In 16S rRNA sequences, clean reads are grouped into functional taxonomic units (OTUs) or amplicon sequence variants (ASVs) based on sequence similarity. Tools such as QIIME (Quantitative Insights Into Microbial Ecology) and DADA2 are often used for this purpose. QIIME facilitates sequence fragmentation against reference databases, such as Green genes or SILVA databases, to identify and quantify microbial populations in samples. DADA2, on the other hand, provides a more sophisticated approach by equally divergent sequences, developing MEGAHIT or SPAdes for metagenomic data on reads using links such as assembled into adjacent sequences (contigs). These contigs are then annotated using databases such as KEGG (Kyoto Encyclopedia of Genes and Genomes), Meta Cyc, or COG (Clusters of Orthologous Groups) to predict genes and assign functions. Tools such as Prokka and MetaPhlan2 help with annotation and taxonomic profiling of collected data. Additionally, shotgun metagenomics allows direct screening of the genes of an entire microbial community, providing insights into the dynamic functions and mechanisms of the microbiome. Statistical analysis is important for complex microbiological data and is interpreted. Diversity measures of alpha such as Shannon and Simpson indices are calculated to assess diversity in individual samples. Beta-diversity metrics, such as Bray-Curtis dissimilarity and UniFrac distance, are used to compare microbial communities between different samples. Principal coordinate analysis (PCoA) and non-metric multidimensional scaling (NMDS) are used for this distinction in their minds. Advanced statistical techniques including PERMANOVA (Permutational Multivariate Analysis of Variance) are used to test for significant differences in bacterial communities based on disease status or other variables. Correlation analysis is an important step that will be linked to microbial profiles and disease progression, aimed at preventing specific microbial communities or Alzheimer's disease (AD), Parkinson's disease (PD), or disease of functions associated with the severity and progression of generative diseases. This review begins by normalizing microbial abundance data to account for variation in sequencing depth between samples to be determined. Relevant quantitative data are often transformed using methods such as log transformation or centralized log-ratio transformation to address the assumptions of downstream statistical tests. Spearman rank correlation and Pearson correlation are commonly used to assess associations between microbial counts and clinical variables, such as cognitive scores, motor function assessments, and biomarkers of neurodegeneration. These correlations help identify microbial taxa with or their number correlates with disease severity. For example, a significant negative correlation between a beneficial virus and cognitive impairment may suggest a protective role of these microorganisms against AD development. Several methods such as canonical correspondence analysis (CCA) and redundancy analysis (RDA) are used to examine the relationship between simultaneous environmental or clinical variables and several pathways of microorganisms associated with disease and helps to uncover the complex interactions between different factors. Furthermore, machine learning techniques, such as random forests and vector-assisted machines, are widely used in microbiological data to identify key microbial parameters that predict disease status. Such a model can be trained on microbiological data to classify samples based on disease presence or developmental stage. Network analysis is another powerful tool that can be used to investigate microbial-host interactions within a microbial community. Symbiotic

interactions reveal potentially synergistic or antagonistic relationships between microbial communities, which can be further explored to understand their role in disease processes. For example, some bacterial inflammation can coexist with low levels of beneficial microorganisms, contributing to the associated dysbiotic state of neurodegenerative disease.

3.4 Validation of Findings

Validation of key findings from research on the role of intestinal bacteria in inflammatory diseases is important to ensure the reliability and reproducibility of the results. This validation can be achieved through various methods including the use of animal models and *in vitro* studies.

Animal Models.

Germ-free (GF) mice raised under sterile conditions lack the microbiome, is a powerful tool for studying the impact of the gut microbiome in neurological diseases. Researchers can use patients with neurodegenerative diseases of the gut microbiota have emerged in these mice and observed consequent motor behavioral changes, for example, during Parkinson's disease (PD). NK-Microbiotics When transplanted into GF mice, these mice tend to exhibit immunodeficiency and enhance alpha-synuclein accumulation, mirroring human PD pathology. This approach helps to correlate directly occurs between specific microbial communities and disease phenotype.

Transgenic mice genetically engineered to express human genes associated with Alzheimer's disease (AD) or PD are valuable in understanding the progression of these diseases in terms of gut microbiota changes. These mice can be used to test the effects of dietary changes, probiotics, or antibiotics on disease progression. For example, researchers can measure how changes in the gut microbiota affect amyloid plaque formation in AD models or dopamine neuron damage in PD models. Behavioral analyzes such as the Morris water maze (for cognition) activity and the rotarod test (for metabolic synergies) are further validated for gut microbial effects in terms of disease symptoms.

In Vitro Studies :

In vitro studies using cell culture models allow detailed investigation of specific cellular and molecular pathways. Neuronal cell lines or primary neurons can be cultured with microbial metabolites such as short-chain fatty acids (SCFAs) or bacterial lipopolysaccharides (LPS) and these studies can reveal how these metabolites affect neuronal survival, synaptic plasticity, and neuroprotective genes the disclosure of the. For example, butyrate, an SCFA, has been shown to increase nerve life and reduce atherosclerosis.

Given the central role of neuroinflammation in neurodegenerative diseases, microglia and astrocytes produced from microbial fractions provide insights into the immune system modulators. Researchers can measure cytokine production, phagocytic activity and signaling activation in response to SCFA or LPS exposure. These studies help to elucidate how gut bacteria-induced changes in immune cell function contribute to the pathogenesis of rheumatoid arthritis.

Brain organoids, which are three-dimensional structures derived from human stem cells that mimic aspects of brain development and function, provide an advanced model *in vitro*. By incubating brain organoids with fetal bacteria or their metabolites using collaborative emphasis, researchers can study the neuronal structure of the brain, Neuronal connections and cellular connections can see direct effects. This model allows closer human brain anatomical anatomy compared to cells of common culture.

Metabolomics and proteomics involve analysis of the metabolome and proteome of biological samples from animal models as well as *in vitro* analysis. Mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy can identify specific metabolites and proteins associated with disease states and microbial profiles. These assays help validate biochemical changes associated with gut bacterial changes.

Sequencing technologies such as RNAseq are used to assess changes in gene expression in response to microbial exposure in animal and cell models. This assay contributes to the discovery of molecular mechanisms influenced by gut microbiota that may contribute to neurodegeneration. It provides a comprehensive view of how the gut microbiome modulates gene expression related to neurodegeneration.

4. RESULTS

4.1 Microbial Profiles of Neurodegenerative Disease Patients

They analyzed the microbiota profiles of patients with Alzheimer's disease (AD) and Parkinson's disease (PD) and compared them with healthy controls and found significant changes in gut microbiota composition in AD patients. There was a significant decrease in the number of anti-inflammatory bacteria such as *Eubacterium* and *Bifidobacterium*, as well as an increase in pro-inflammatory bacteria such as *Escherichia/Shigella*. This infection is associated with increased intestinal permeability and systemic inflammatory markers. . . . A similar pattern of dysbiosis was observed in PD patients, with a decrease in beneficial SCFA-producing bacteria such as *Faecalibacterium roseburia* and an increase in potential pathogens such as *Enterobacteriaceae*. These changes were more pronounced in comparison of healthy controls, who exhibited a more balanced gut microbiota with greater diversity and stability.

4.2 Correlation Between Gut Microbiota and Disease Progression

The study revealed several key viruses associated with the severity of rheumatoid arthritis diseases. The density of *Escherichia/Shigella* in AD patients was positively associated with moderate cognitive impairment, as measured by Mini-

Mental Status Examination (MMSE) scores and with the reduction of Faecalibacterium roseburia in PD patients severe muscle dysfunction is correlated, as is the combined rate of Parkinson's disease. Metabolic pathway analysis assessed by scale (UPDRS) showed that these microbial changes may affect several important pathways including SCFA synthesis, metabolism of neurotransmitters such as serotonin and dopamine, and modulation of immune responses Dysbiosis was associated with decreased production of butyrate, which of SCFA by are well known for their inhibitory effects on neuroprotection, and may increase the incidence of arthritis and tissue damage.

4.3 Identification of Therapeutic Targets

Several microbes and metabolites were identified as potential therapeutic targets for reducing AD and PD symptoms. The increased prevalence of pro-pathogenic Escherichia/Shigella in AD patients and the decreased prevalence of resistant Eubacterium and Bifidobacterium in AD patients suggest that targeting these bacteria may contribute to microbial restoration a positive balance with SCFAs such as Faecalibacterium and Roseburia has also occurred in PD patients. Increasing the abundance of productive bacteria can improve metabolic function and reduce inflammation Potential interventions include the use of probiotics, prebiotics, and dietary modifications to select beneficial microorganisms they have grown on it. In addition, butyrate and other metabolites could be explored as direct chemotherapeutic agents and harness their neuroprotective effects.

TABLE III. COMPARATIVE ANALYSIS OF MICROBIAL PROFILES AND DISEASE PROGRESSION PARAMETERS IN ALZHEIMER'S, PARKINSON'S, AND HEALTHY CONTROLS

Parameter	Alzheimer's Patients	Parkinson's Patients	Healthy Controls
Anti-inflammatory Bacteria	Decreased (Eubacterium, Bifidobacterium)	Decreased (Faecalibacterium, Roseburia)	Higher abundance (Eubacterium, Bifidobacterium, Faecalibacterium, Roseburia)
Pro-inflammatory Bacteria	Increased (Escherichia/Shigella)	Increased (Enterobacteriaceae)	Lower abundance (Escherichia/Shigella, Enterobacteriaceae)
SCFA Production	Reduced	Reduced	Normal
Intestinal Permeability	Increased	Increased	Normal
Systemic Inflammation Markers	Elevated	Elevated	Normal
Cognitive Function (MMSE Score)	Correlated with increased Escherichia/Shigella (lower MMSE scores)	N/A	Higher scores, balanced microbiota
Motor Function (UPDRS Score)	N/A	Correlated with decreased Faecalibacterium, Roseburia (higher UPDRS scores)	Better scores, balanced microbiota
Potential Therapeutic Targets	Escherichia/Shigella, Eubacterium, Bifidobacterium	Faecalibacterium, Roseburia, SCFAs	N/A

The results show a more diverse microbiome in Alzheimer's and Parkinson's disease patients compared to healthy controls. The observed association between specific microbes and disease severity highlights the potential role of the gut microbiota in the pathogenesis of rheumatoid arthritis If these dysbiotic variables are targeted through therapeutic interventions, can reduce symptoms and improve quality of life in individuals with AD and PD.

5. DISCUSSION

The findings of this study highlight the important association between the gut microbiota and neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD). It suggests that they play an important role in the pathophysiology of these diseases In particular, the decrease in SCFA-producing bacteria such as Faecalibacterium and Roseburia in PD patients and Eubacterium and Bifidobacterium in AD patients indicate if gut condition is impaired it can lead to arthritis and subsequent nerve damage. Increased numbers of inflammatory bacteria such as Escherichia/Shigella and Enterobacteriaceae further support this hypothesis, as these bacteria are known to exacerbate systemic inflammatory responses Increased cervical mucus in various ways a can occur linking gut microbiota to infection, commonly referred to as " gut permeability and endotoxins can enter the blood stream and transmit these neurological diseases to the brain Chronic inflammation can be presented as a primary cause." promoting Furthermore, the ability of the gut microbiota to produce neurotransmitters such as SCFA, serotonin, and dopamine suggests that dysbiosis may directly affect neuronal metabolism and signaling, and thus affected renal function Negative correlation between renal decline and Escherichia/Shigella levels in AD, and faecalibacterium motor disorders The association between roseburia and low levels highlights the significant impact of microbial a formation achieves on vascular health confirms research findings opens exciting possibilities for microbial-based therapies to treat inflammatory vascular diseases Probiotics, which are beneficial live bacteria, can be used to restore a healthy balance of gut bacteria, and can reduce inflammation and improve mental and physical functioning independently of digestive factors will be introduced, such as high fiber-rich foods can promote the growth of SCFA-producing bacteria

Another promising technique is fecal microbiome transplantation (FMT), where feces from a healthy donor administered into the patient's gut to restore a balanced microbiota FMT has demonstrated success in the treatment of gastrointestinal disorders and rheumatoid arthritis. The gut microbiota is highly individual, influenced by genetics, diet, environment, and other factors, making it difficult to develop one-size-fits-all treatments. Furthermore, the safety and efficacy of long-term microbial therapy should be fully evaluated through clinical trials. Ethical considerations and legal constraints need to be addressed, especially for interventions such as FMT. Another consideration is the potential for unintended consequences such as harmful bacteria caused by probiotics or FMT. Thus, while the potential of viral-based therapies is promising, careful, individualized approaches and strong clinical evidence are needed for their successful application in neurological diseases in the treatment.

6. CONCLUSION

This study provides strong evidence linking gut microbiota diversity to the pathogenesis and progression of neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD). AD patients showed a decrease in beneficial bacteria like Eubacterium and Bifidobacterium and an increase in inflammatory pathogens like Escherichia/Shigella. Similarly, PD patients showed lower levels of SCFA-producing bacteria like Faecalibacterium roseburia. On high numbers of Enterobacteriaceae. These microbial changes correlated with disease severity: Escherichia/Shigella levels in AD correlated negatively with cognitive function (MMSE score), whereas lower levels of Faecalibacterium and Roseburia in PD with poor motor function (UPDRS score) is associated. Also, metabolic analysis showed dysbiosis SCFA production. It can also affect neurotransmitter metabolism, which can increase the risk of arthritis and nerve damage. The findings suggest whether restoring a healthy gut microbiota may be a promising therapeutic strategy for these neurological diseases. Potential interventions include the use of probiotics to increase beneficial bacteria, dietary modifications to promote SCFA production, fecal microbial transplantation (FMT) to restore microbial balance. But translating these data into clinical practice requires careful consideration of individual treatments, long-term safety and legal and ethical challenges.

References

- [1] A. Baysoy, Z. Bai, R. Satija, and R. Fan, "The technological landscape and applications of single-cell multi-omics," *Nature Reviews Molecular Cell Biology*, vol. 24, pp. 695–713, 2023.
- [2] F. Li, J. Yin, M. Lu, Q. Yang, Z. Zeng, B. Zhang, Z. Li, Y. Qiu, H. Dai, Y. Chen, and F. Zhu, "ConSIG: consistent discovery of molecular signature from OMIC data," *Briefings in Bioinformatics*, vol. 23, no. 4, pp. 1–11, Jul. 2022, doi: 10.1093/bib/bbac253.
- [3] Y. Han et al., "The fusion of multi-omics profile and multimodal EEG data contributes to the personalized diagnostic strategy for neurocognitive disorders," *Microbiome*, vol. 12, no. 1, p. 12, 2023.
- [4] X. Liu et al., "Correlation between the gut microbiome and neurodegenerative diseases: A review of metagenomics evidence," *Neural Regeneration Research*, vol. 19, no. 4, pp. 833–845, 2023.
- [5] N. Estanyol-Torres, C. Domenech-Coca, R. G. Domínguez, A. Miñarro, et al., "A mixture of four dietary fibres ameliorates adiposity and improves metabolic profile and intestinal health in cafeteria-fed obese rats: an integrative multi-omics approach," *The Journal of Nutritional Biochemistry*, vol. 111, p. 109184, Jan. 2023.
- [6] D. A. Kieffer et al., "Resistant starch alters gut microbiome and metabolomic profiles concurrent with amelioration of chronic kidney disease in rats," *American Journal of Physiology–Renal Physiology*, vol. 310, no. 9, 2016, doi: 10.1152/ajprenal.00513.2015.
- [7] J. F. Cryan and T. G. Dinan, "Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour," *Nat. Rev. Neurosci.*, vol. 13, no. 10, pp. 701–712, Oct. 2012.
- [8] T. R. Sampson et al., "Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease," *Cell*, vol. 167, no. 6, pp. 1469–1480, Dec. 2016.
- [9] N. M. Vogt et al., "Gut microbiome alterations in Alzheimer's disease," *Sci. Rep.*, vol. 7, no. 1, p. 13537, Oct. 2017.
- [10] R. Xu and Q. Wang, "Towards understanding brain-gut-microbiome connections in Alzheimer's disease," *BMC Syst. Biol.*, vol. 14, no. 1, p. 82, May 2020.
- [11] T. Behl, A. Sharma, L. Sharma, A. Sehgal, G. Zengin, R. Brata, O. Fratila, and S. Bungau, "Exploring the multifaceted therapeutic potential of withaferin A and its derivatives," *Biomedicines*, vol. 8, no. 12, p. 571, 2020, doi: 10.3390/biomedicines8120571.
- [12] J. Kim, H. R. Woo, and H. G. Nam, "Toward systems understanding of leaf senescence: An integrated multi-omics perspective on leaf senescence research," *Molecular Plant*, vol. 9, no. 6, pp. 813–825, Jun. 2016.
- [13] N. B. Danneskiold-Samsøe, H. D. F. Q. Barros, R. Santos, J. L. Bicas, C. B. B. Cazarin, L. Madsen, K. Kristiansen, G. M. Pastore, S. Brix, and M. R. Maróstica Júnior, "Interplay between food and gut microbiota in health and disease," *Food Research International*, vol. 115, pp. 23–31, Jan. 2019.
- [14] M. Duan, Y. Wang, Q. Zhang, R. Zou, M. Guo, and H. Zheng, "Characteristics of gut microbiota in people with obesity," *PLOS One*, Aug. 10, 2021, doi: 10.1371/journal.pone.0255446.
- [15] A. Kaiyrylykzy et al., "Study of gut microbiota alterations in Alzheimer's dementia patients from Kazakhstan," *Scientific Reports*, vol. 12, Art. no. 15115, 2022.

- [16] L. Bonfili, M. Cuccioloni, C. Gong, V. Cecarini, M. Spina, Y. Zheng, M. Angeletti, and A. M. Eleuteri, "Gut microbiota modulation in Alzheimer's disease: Focus on lipid metabolism," *Clinical Nutrition*, vol. 41, no. 3, pp. 698–708, Mar. 2022
- [17] I. Subramanian, S. Verma, S. Kumar, A. Jere, and K. Anamika, "Multi-omics data integration, interpretation, and its application," *Sage Journals*, 2020, doi: 10.1177/1177932219899051.
- [18] W. A. da Silveira, H. Fazelinia, S. B. Rosenthal, E. C. Laiakis, et al, "Comprehensive multi-omics analysis reveals mitochondrial stress as a central biological hub for spaceflight impact," *Cell Journal*, vol. 183, no. 5, pp. 1185–1201.e20, Nov. 2020.
- [19] D. Chen, X. Zhao, Z. Sui, H. Niu, L. Chen, C. Hu, Q. Xuan, X. Hou, R. Zhang, L. Zhou, Y. Li, H. Yuan, Y. Zhang, J. Wu, L. Zhang, R. Wu, H.-L. Piao, G. Xu, and W. Jia, "A multi-omics investigation of the molecular characteristics and classification of six metabolic syndrome relevant diseases," *Theranostics*, vol. 10, no. 5, pp. 2029–2046, 2020, doi: 10.7150/thno.41106.
- [20] M. E. Gallo Cantafio, K. Grillone, D. Caracciolo, F. Scionti, M. Arbitrio, V. Barbieri, L. Pensabene, P. H. Guzzi, and M. T. Di Martino, "From single level analysis to multi-omics integrative approaches: A powerful strategy towards the precision oncology," in *The Road from Nanomedicine to Precision Medicine*, 1st ed., Jenny Stanford Publishing, 2020, pp. 41, eBook ISBN: 9780429295010.
- [21] F. Crouwel, H. J. C. Buiters, and N. K. de Boer, "Gut microbiota-driven drug metabolism in inflammatory bowel disease," *Journal of Crohn's and Colitis*, vol. 15, no. 2, pp. 307–315, Feb. 2021, doi: 10.1093/ecco-jcc/jjaa143.
- [22] B. Zhang, J. Zhao, P. Guo, Z. Wang, L. Xu, A. Liu, and G. Du, "Effects of Naodesheng tablets on amyloid beta-induced dysfunction: A traditional Chinese herbal formula with novel therapeutic potential in Alzheimer's disease revealed by systems pharmacology," *Biomedicine & Pharmacotherapy*, vol. 141, p. 111916, Sep. 2021.
- [23] M. H. Shahrajabian and W. Sun, "Survey on multi-omics, and multi-omics data analysis, integration and application," *Current Pharmaceutical Analysis*, vol. 19, no. 4, pp. 267–281, 2023, doi: 10.2174/1573412919666230406100948.
- [24] Y. Hasin, M. Seldin, and A. Lusic, "Multi-omics approaches to disease," *Genome Biology*, vol. 18, Art. no. 83, 2017.
- [25] H. J. Flint, K. P. Scott, P. Louis, and S. H. Duncan, "The role of the gut microbiota in nutrition and health," *Nature Reviews Gastroenterology & Hepatology*, vol. 9, pp. 577–589, 2012.